AlphaLiquidⓇ100

AlphaLiquidⓇ100 is a liquid biopsy test designed for patients with advanced solid cancers. Our patented UniqSeqⓇ technology detects minuscule amount of ctNDA (circulating tumor NDA) in the bloodstream for comprehensive genomic analysis.

AlphaLiquidⓇ100 detects the four classes of variations (SNV, INDEL, fusion, and CNV) in 106 NCCN-recommended genes associated with major cancer types. With this data, IMB Dx can provide information on appropriate therapy options and related on-going clinical trials.

Recommended for:

  • Patients who are unable to go through invasive tissue biopsy.
  • Patients whose tumor tissue cannot be obtained.
  • Patients who have not been tested for a long time, or whose tissue biopsy result is outdated.
  • Patients with more than one key mutations detected from recent biopsy.
  • Patients who need more than a single gene test for appropriate diagnosis and therapy.

AlphaLiquidⓇ100 Workflow

AlphaLiquidⓇ100 Workflow

106 Gene List

Includes genes related to solid tumors recommended by NCCN. Tested for the four mutations (SNVs, INDEL, fusion, CNVs) and MSI.

ABL1 AKT1 AKT2 ALK* APC AR ARAF ARID1A ATM BCR**
BRAF* BRCA1 BRCA2 BTK CBL CCND1 CCND2 CCNE1 CD274 CDH1
CDK4 CDK6 CDKN2A CEBPA CSF1R CTNNB1 DDR2 DPYD EGFR ERBB2
CDK4 CDK6 CDKN2A CEBPA CSF1R CTNNB1 DDR2 DPYD EGFR ERBB2
ERBB3 ESR1 FBXW7 FGFR1 FGFR2* FGFR3* FLT3 GATA3 GNA11 GNAQ
GNAS HRAS IDH1 IDH2 IGF1R JAK2 JAK3 KDM6A KDR KEAP1
GNAS HRAS IDH1 IDH2 IGF1R JAK2 JAK3 KDM6A KDR KEAP1
KIT KRAS MAP2K1 MAP2K2 MAPL1 MAPK3 MDM2 MET MLH1 MPL
MSH2 MSH6 MTOR MYC MYCN NF1 NF2 NFE2L2 NOTCH1 NPM1
NRAS NTRK1* NTRK2* NTRK3 PDCD1LG2 PDGFRA PDGFRB PIK3CA PIK3R1 PMS2
PPP2R1A PTEN PTPN11 RAF1 RB1 RET* RHEB RHOA RIT1 RNF43
ROS1* RUNX1 SETD2 SMAD4 SMO STAG2 STK11 TCF7L2 TERT*** TOP2A
TP53 TSC1 TSC2 U2AF1 UGT1A1 VHL        

Concordance with Tissue Data

Analyzed based on data from:
  • Patients subject to the 10K Project.
  • Patients before first-line therapy for lung, colorectal, and breast cancer.
  • Patients participating in clinical trials carried out by the KFDA.
  • Patients participating in clinical trials carried out by major hospitals in Seoul.
90-100%
concordance

Recommended for patients before anticancer therapy or with cancer in progress.